GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thor Medical ASA (LTS:0R6Y) » Definitions » EV-to-EBITDA

Thor Medical ASA (LTS:0R6Y) EV-to-EBITDA : (As of May. 14, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Thor Medical ASA EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Thor Medical ASA's enterprise value is kr195.53 Mil. Thor Medical ASA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was kr0.00 Mil. Therefore, Thor Medical ASA's EV-to-EBITDA for today is .

The historical rank and industry rank for Thor Medical ASA's EV-to-EBITDA or its related term are showing as below:

LTS:0R6Y' s EV-to-EBITDA Range Over the Past 10 Years
Min: -41.53   Med: -1.95   Max: 1.42
Current: -40.37

During the past 13 years, the highest EV-to-EBITDA of Thor Medical ASA was 1.42. The lowest was -41.53. And the median was -1.95.

LTS:0R6Y's EV-to-EBITDA is ranked worse than
100% of 463 companies
in the Biotechnology industry
Industry Median: 9.32 vs LTS:0R6Y: -40.37

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-14), Thor Medical ASA's stock price is kr1.04. Thor Medical ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was kr0.000. Therefore, Thor Medical ASA's PE Ratio for today is N/A.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Thor Medical ASA EV-to-EBITDA Historical Data

The historical data trend for Thor Medical ASA's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thor Medical ASA EV-to-EBITDA Chart

Thor Medical ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.93 -2.39 -4.64 3.56 -53.68

Thor Medical ASA Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.22 -0.01 3.56 - -53.68

Competitive Comparison of Thor Medical ASA's EV-to-EBITDA

For the Biotechnology subindustry, Thor Medical ASA's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thor Medical ASA's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thor Medical ASA's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Thor Medical ASA's EV-to-EBITDA falls into.



Thor Medical ASA EV-to-EBITDA Calculation

Thor Medical ASA's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=195.525/0
=

Thor Medical ASA's current Enterprise Value is kr195.53 Mil.
Thor Medical ASA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Thor Medical ASA  (LTS:0R6Y) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Thor Medical ASA's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.04/0.000
=N/A

Thor Medical ASA's share price for today is kr1.04.
Thor Medical ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Thor Medical ASA EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Thor Medical ASA's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Thor Medical ASA (LTS:0R6Y) Business Description

Traded in Other Exchanges
Address
Kjelsasveien 168 B, Oslo, NOR, 0884
Nordic Nanovector ASA is a biopharmaceutical company. It is engaged in the development and commercialization of targeted therapeutics to improve the lives of patients with haematological cancers, such as non-Hodgkin lymphoma and leukaemia. The company's main clinical stage product is Betalutin.

Thor Medical ASA (LTS:0R6Y) Headlines

No Headlines